Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article
- PMID: 28824858
- PMCID: PMC5556397
- DOI: 10.5812/aapm.42747
Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article
Abstract
Context: Visceral pain is a leading symptom for patients with irritable bowel syndrome (IBS) that affects 10% - 20 % of the world population. Conventional pharmacological treatments to manage IBS-related visceral pain is unsatisfactory. Recently, medications have emerged to treat IBS patients by targeting the gastrointestinal (GI) tract and peripheral nerves to alleviate visceral pain while avoiding adverse effects on the central nervous system (CNS). Several investigational drugs for IBS also target the periphery with minimal CNS effects.
Evidence of acquisition: In this paper, reputable internet databases from 1960 - 2016 were searched including Pubmed and ClinicalTrials.org, and 97 original articles analyzed. Search was performed based on the following keywords and combinations: irritable bowel syndrome, clinical trial, pain, visceral pain, narcotics, opioid, chloride channel, neuropathy, primary afferent, intestine, microbiota, gut barrier, inflammation, diarrhea, constipation, serotonin, visceral hypersensitivity, nociceptor, sensitization, hyperalgesia.
Results: Certain conventional pain managing drugs do not effectively improve IBS symptoms, including NSAIDs, acetaminophen, aspirin, and various narcotics. Anxiolytic and antidepressant drugs (Benzodiazepines, TCAs, SSRI and SNRI) can attenuate pain in IBS patients with relevant comorbidities. Clonidine, gabapentin and pregabalin can moderately improve IBS symptoms. Lubiprostone relieves constipation predominant IBS (IBS-C) while loperamide improves diarrhea predominant IBS (IBS-D). Alosetron, granisetron and ondansetron can generally treat pain in IBS-D patients, of which alosetron needs to be used with caution due to cardiovascular toxicity. The optimal drugs for managing pain in IBS-D and IBS-C appear to be eluxadoline and linaclotide, respectively, both of which target peripheral GI tract.
Conclusions: Conventional pain managing drugs are in general not suitable for treating IBS pain. Medications that target the GI tract and peripheral nerves have better therapeutic profiles by limiting adverse CNS effects.
Keywords: Clinical Trial; Constipation; Diarrhea; Hyperalgesia; Irritable Bowel Syndrome; Visceral Hypersensitivity; Visceral Pain.
Similar articles
-
Treatment of irritable bowel syndrome.J Clin Pharm Ther. 2011 Jun;36(3):275-82. doi: 10.1111/j.1365-2710.2010.01177.x. Epub 2010 Aug 24. J Clin Pharm Ther. 2011. PMID: 21545610 Review.
-
Irritable bowel syndrome: new pharmaceutical approaches to treatment.Baillieres Best Pract Res Clin Gastroenterol. 1999 Oct;13(3):461-71. doi: 10.1053/bega.1999.0040. Baillieres Best Pract Res Clin Gastroenterol. 1999. PMID: 10580922 Review.
-
Novel pharmacological therapies for irritable bowel syndrome.Expert Rev Gastroenterol Hepatol. 2016 Jul;10(7):807-15. doi: 10.1586/17474124.2016.1158099. Epub 2016 Mar 18. Expert Rev Gastroenterol Hepatol. 2016. PMID: 26907518 Review.
-
Management of irritable bowel syndrome with diarrhea: focus on eluxadoline.Curr Med Res Opin. 2021 Apr;37(4):567-578. doi: 10.1080/03007995.2021.1888705. Epub 2021 Mar 3. Curr Med Res Opin. 2021. PMID: 33566707
-
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.Drugs. 2001;61(3):317-32. doi: 10.2165/00003495-200161030-00001. Drugs. 2001. PMID: 11293643 Review.
Cited by
-
Blocking Aδ- and C-fiber neural transmission by sub-kilohertz peripheral nerve stimulation.Front Neurosci. 2024 Jul 15;18:1404903. doi: 10.3389/fnins.2024.1404903. eCollection 2024. Front Neurosci. 2024. PMID: 39077428 Free PMC article.
-
Evaluation of the mechanism of action of paracetamol, drotaverine, and peppermint oil and their effects in combination with hyoscine butylbromide on colonic motility: human ex-vivo study.Front Pharmacol. 2024 Jul 10;15:1384070. doi: 10.3389/fphar.2024.1384070. eCollection 2024. Front Pharmacol. 2024. PMID: 39050750 Free PMC article.
-
Complex visceral hyperalgesia in an adolescent with Pitt-Hopkins syndrome.BMJ Case Rep. 2024 Feb 19;17(2):e258257. doi: 10.1136/bcr-2023-258257. BMJ Case Rep. 2024. PMID: 38373809
-
Systematic Review on Herbal Preparations for Controlling Visceral Hypersensitivity in Functional Gastrointestinal Disorders.Curr Pharm Biotechnol. 2024;25(13):1632-1650. doi: 10.2174/0113892010261502231102040149. Curr Pharm Biotechnol. 2024. PMID: 38258770
-
Effects of Duloxetine on Gastrointestinal Symptoms, Depression, Anxiety, Stress, and Quality of Life in Patients with the Moderate-to-Severe Irritable Bowel Syndrome.Adv Biomed Res. 2023 Nov 29;12:249. doi: 10.4103/abr.abr_379_21. eCollection 2023. Adv Biomed Res. 2023. PMID: 38192887 Free PMC article.
References
-
- Feng B, La JH, Schwartz ES, Gebhart GF. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;302(10):G1085–98. doi: 10.1152/ajpgi.00542.2011. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials